SG11201807974QA - Arginase inhibitors and their therapeutic applications - Google Patents

Arginase inhibitors and their therapeutic applications

Info

Publication number
SG11201807974QA
SG11201807974QA SG11201807974QA SG11201807974QA SG11201807974QA SG 11201807974Q A SG11201807974Q A SG 11201807974QA SG 11201807974Q A SG11201807974Q A SG 11201807974QA SG 11201807974Q A SG11201807974Q A SG 11201807974QA SG 11201807974Q A SG11201807974Q A SG 11201807974QA
Authority
SG
Singapore
Prior art keywords
therapeutic applications
arginase inhibitors
arginase
inhibitors
therapeutic
Prior art date
Application number
SG11201807974QA
Other languages
English (en)
Inventor
Roman Blaszczyk
Julita Nowicka
Bartlomiej Borek
Joanna Brzezinska
Anna Gzik
Marek Dziegielewski
Adam Golebiowski
Karol Jedrzejczak
Krzysztof Matyszewski
Jacek Olczak
Original Assignee
Oncoarendi Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoarendi Therapeutics Sa filed Critical Oncoarendi Therapeutics Sa
Publication of SG11201807974QA publication Critical patent/SG11201807974QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201807974QA 2016-05-04 2017-05-02 Arginase inhibitors and their therapeutic applications SG11201807974QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662331550P 2016-05-04 2016-05-04
PL417066A PL417066A1 (pl) 2016-05-04 2016-05-04 Inhibitory arginazy oraz ich zastosowania terapeutyczne
US201762444669P 2017-01-10 2017-01-10
PCT/EP2017/060413 WO2017191130A2 (en) 2016-05-04 2017-05-02 Arginase inhibitors and their therapeutic applications

Publications (1)

Publication Number Publication Date
SG11201807974QA true SG11201807974QA (en) 2018-10-30

Family

ID=60190450

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807974QA SG11201807974QA (en) 2016-05-04 2017-05-02 Arginase inhibitors and their therapeutic applications

Country Status (24)

Country Link
US (3) US10391077B2 (ko)
EP (1) EP3452485B1 (ko)
JP (1) JP6971477B2 (ko)
KR (1) KR102374788B1 (ko)
CN (1) CN109415387B (ko)
AU (1) AU2017259887B2 (ko)
BR (1) BR112018072545B1 (ko)
CA (1) CA3022482C (ko)
CL (1) CL2018003132A1 (ko)
CO (1) CO2018013077A2 (ko)
DK (1) DK3452485T3 (ko)
ES (1) ES2834065T3 (ko)
HR (1) HRP20201821T1 (ko)
HU (1) HUE052468T2 (ko)
IL (1) IL262387B (ko)
LT (1) LT3452485T (ko)
MX (1) MX2018013387A (ko)
PE (1) PE20181924A1 (ko)
PH (1) PH12018501976A1 (ko)
PL (2) PL417066A1 (ko)
SA (1) SA518400356B1 (ko)
SG (1) SG11201807974QA (ko)
SI (1) SI3452485T1 (ko)
WO (1) WO2017191130A2 (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2632927B1 (en) 2010-10-26 2016-02-10 Mars, Incorporated Boronates as arginase inhibitors
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
AU2016343656B2 (en) 2015-10-30 2020-09-17 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
RS64770B1 (sr) 2016-03-07 2023-11-30 Agrofresh Inc Sinergistički postupci upotrebe jedinjenja benzoksaborola i gasova za prezerviranje kao antimikrobnih agenasa za useve
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
SG11202007739XA (en) 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
CA3091805A1 (en) * 2018-03-05 2019-09-12 Arcus Biosciences, Inc. Arginase inhibitors
US20210040127A1 (en) * 2018-03-13 2021-02-11 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
TWI723366B (zh) * 2018-03-29 2021-04-01 波蘭商昂科艾倫迪治療法股份公司 二肽哌啶衍生物
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
WO2020131598A1 (en) * 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
EP4087583A4 (en) * 2020-01-07 2024-01-24 Merck Sharp & Dohme Llc ARGINASE INHIBITORS AND METHODS OF USE
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
EP1049660A1 (en) * 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
EP1604977A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals CIS pyrrolidinyl derivatives and their uses
EP1604978A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals Trans pyrrolidinyl derivatives and their pharmaceutical uses
EP2083812B1 (en) 2006-11-21 2017-04-05 Rijksuniversiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
HUE046932T2 (hu) 2009-01-26 2020-04-28 Univ Pennsylvania Argináz inhibitorok és felhasználási eljárások
CN103068830B (zh) 2010-04-22 2016-06-29 马尔斯公司 精氨酸酶抑制剂及其治疗应用
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
EP2632927B1 (en) * 2010-10-26 2016-02-10 Mars, Incorporated Boronates as arginase inhibitors
EP2658580A4 (en) 2010-12-31 2014-07-23 Corridor Pharmaceuticals Inc ARGINE STARTER AND USE METHOD
WO2013059437A1 (en) 2011-10-19 2013-04-25 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
JP6152167B2 (ja) * 2012-04-18 2017-06-21 マーズ インコーポレイテッド アルギナーゼ阻害剤としての環拘束性類似体
PL2872515T3 (pl) 2012-07-13 2017-05-31 Janssen Sciences Ireland Uc Puryny makrocykliczne do leczenia infekcji wirusowych
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2016281620B2 (en) 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
AU2016343656B2 (en) 2015-10-30 2020-09-17 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US11291674B2 (en) 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
WO2019145453A1 (en) 2018-01-28 2019-08-01 Universite De Geneve Arginase suppression for cancer treatment

Also Published As

Publication number Publication date
US10391077B2 (en) 2019-08-27
IL262387A (en) 2018-12-31
PH12018501976A1 (en) 2019-07-01
BR112018072545B1 (pt) 2022-08-23
BR112018072545A2 (pt) 2019-06-25
HRP20201821T1 (hr) 2021-04-16
CL2018003132A1 (es) 2019-02-22
JP2019518726A (ja) 2019-07-04
AU2017259887A1 (en) 2018-09-27
EP3452485B1 (en) 2020-09-09
AU2017259887B2 (en) 2022-03-17
JP6971477B2 (ja) 2021-11-24
CN109415387A (zh) 2019-03-01
US20190365701A1 (en) 2019-12-05
WO2017191130A4 (en) 2018-03-01
CA3022482A1 (en) 2017-11-09
MX2018013387A (es) 2019-02-28
US20170319536A1 (en) 2017-11-09
CN109415387B (zh) 2021-08-27
DK3452485T3 (da) 2020-11-09
LT3452485T (lt) 2020-12-28
PL3452485T3 (pl) 2021-04-19
CO2018013077A2 (es) 2019-04-30
WO2017191130A2 (en) 2017-11-09
WO2017191130A3 (en) 2017-12-14
US20210260019A1 (en) 2021-08-26
IL262387B (en) 2021-10-31
HUE052468T2 (hu) 2021-04-28
CA3022482C (en) 2024-06-11
US10912755B2 (en) 2021-02-09
KR20190015250A (ko) 2019-02-13
EP3452485A2 (en) 2019-03-13
PL417066A1 (pl) 2017-11-06
ES2834065T3 (es) 2021-06-16
PE20181924A1 (es) 2018-12-11
KR102374788B1 (ko) 2022-03-15
SA518400356B1 (ar) 2022-01-19
SI3452485T1 (sl) 2021-01-29

Similar Documents

Publication Publication Date Title
IL262387A (en) Arginase inhibitors and their treatment applications
IL265922A (en) tyk2 inhibitors and uses thereof
HK1256796A1 (zh) 二價溴結構域抑制劑及其用途
HK1249513A1 (zh) Kras的稠合三環抑制劑及其使用方法
IL266109A (en) tyk2 inhibitors and uses thereof
HK1243072A1 (zh) 布羅莫結構域抑制劑及其用途
IL267291A (en) Actonucleotidase inhibitors and methods of using them
GB201605126D0 (en) Inhibitors and their uses
PL3240777T3 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
IL262251B1 (en) New anti-syrap antibodies and their medical applications
RS64889B1 (sr) Inhibitori lsd1 i njihova medicinska upotreba
EP3359150A4 (en) COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
HUE063120T2 (hu) LRRC33-inhibitorok és alkalmazásuk
IL263949A (en) Complement inhibitors and their uses
KR20180084747A (ko) Galgt2 유전자 치료 방법 및 물질
HK1250926A1 (zh) 抑制劑及其應用
EP3370763A4 (en) CD200 INHIBITORS AND METHODS OF USE
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
IL266344A (en) Inhibitors of mtor-deptor interactions and methods of use thereof
HK1255029A1 (zh) 明膠酶抑制劑及其用途
ZA201808008B (en) Arginase inhibitors and their therapeutic applications
GB201505975D0 (en) Inhibitors and their uses
GB201505971D0 (en) Inhibitors and their uses